Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Biogen trumpets safety data for Tecfidera follow-up

Biogen trumpets safety data for Tecfidera follow-up

2028. Diroximel fumarate is Biogen’s bid to shore up its MS franchise, its biggest earner, and has become even more important since the company’s Alzheimer’s candidate aducanumab was ... Moreover, the firm’s new growth product Spinraza (nusinersen

Latest news

  • AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy AmyPore gets EU backing for Alzheimers and Parkinson’s therapy

    Alzheimer’s and Parkinson’s disease. ... The peptide – called AmyP53 – targets receptors on nerve cells called gangliosides that attract and bind amyloid proteins that are thought to be linked to the pathology of both Alzheimer’s (beta

  • Bicycles Therapeutics enters dementia discovery with venture capital fund Bicycles Therapeutics enters dementia discovery with venture capital fund

    The last decade has been characterised by a disheartening string of late-stage drug failures in Alzheimer’s disease, and this year alone has seen two major programmes crash in the ... Researchers working in the field know that new approaches must be

  • Lundbeck snaps up Abide Therapeutics for $400m Lundbeck snaps up Abide Therapeutics for $400m

    challenging. Efforts to bring forward its own drugs have been undermined by a couple of late-stage failures, including idalopirdine for Alzheimer’s disease and Lu AF35700 for treatment-resistant schizophrenia. ... agreed a $1.1bn deal last year to buy

  • Biogen’s tofersen shows promise in slowing down ALS Biogen’s tofersen shows promise in slowing down ALS

    Biogen is on the look out for strong candidates to boost its prospects, especially after recently conceding defeat on one of its biggest pipeline hopes aducanumab in Alzheimer’s disease. ... Michael Ehlers recently said the company won’t give up on

  • Spinraza keeps Biogen afloat as Tecfidra stalls Spinraza keeps Biogen afloat as Tecfidra stalls

    This adds to a complicated picture for Biogen, which also had to concede defeat on its Alzheimer's candidate aducanumab in March, putting paid to one of its biggest pipeline hopes. ... Michel Vounatsos, Biogen’s chief executive officer said the company

More from news
Approximately 96 fully matching, plus 383 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 4 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

  • 'Fake news': battling misinformation in healthcare

    An article published just three days later, again from ‘The Telegraph’ , plays on the  growing threat of Alzheimer’s. ... This means it can’t currently be stated that retinal changes had occurred before or after the participants Alzheimer’s

  • Havas Lynx shines a spotlight on carers

    Commenting on the white paper’s findings, Havas Lynx CEO, Dave Hunt, said:. ... References:. Alzheimer’s Disease International (2013) http://bit.ly/2nPw6QK (Accessed April 2017). Carers UK (2015)   (Accessed April 2017).

  • Havas Lynx pushes the boundaries of creative healthcare with new recruits

    Lou’s varied portfolio includes powerful and compelling campaigns for Cancer Research UK, Save the Children and Alzheimer’s Society. ... It’s great to see so many high profile and brilliant creatives recognise this and join our mission.

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Please contact us at info@random42.com to arrange a meeting. For more information on Random42’s capabilities please see

  • The dark side of direct-to-consumer genetic tests

    Who can blame them? If an email landed in your inbox that appeared to indicate you had an increased risk of cancer, Parkinson’s disease, Alzheimer’s disease, or any other

More from PMHub
Approximately 3 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics